Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin on BMS-986235 PK in Healthy Participants
NCT04301310Phase 1Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986235 in heart failure (HF), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum plasma concentration of BMS-986235 at Day 1, Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration of BMS-986235 at Day 1 and 4 more. Planned start Mar 2020; status: withdrawn.
02
Drugs
BMS-986235
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04301310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301310.